Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + Pixantrone as Rescue Therapy in Relapsed Aggressive B-cell Lymphoma
DRKS00009416Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab and pixantrone in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mature B-cell lymphoma, sponsored by University Medical Center Mainz. Started Oct 2015; status: completed.
02
Drugs
obinutuzumabpixantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on DRKS00009416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00009416.